MedTrace Logo

Relapse Markers for Colorectal Cancer

NCT04920955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2024-03-19

No results posted yet for this study

Summary

This is an observational case-control study which enroll metastatic and non-metastatic colorectal cancer (CRC) patients. The objective of this study is to evaluate a novel blood multi-marker test for the detection of relapse in colorectal cancer patients. This test is based on whole-blood transcriptomic signatures and circulating tumor methylated DNA markers. The patients will be enrolled into 4 study groups, two cross-sectional and two longitudinal groups, to follow up patients up to 36 months from primary tumor resection.

Conditions

Sponsors & Collaborators

  • Novigenix SA

    lead OTHER

Principal Investigators

  • Laura Ciarloni · Novigenix SA

  • Sabine Tejpar · UZ Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2023-12-31
Completion
2024-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920955 on ClinicalTrials.gov